# Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis

> **NCT01115582** · PHASE3 · COMPLETED · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Inborn Errors of Bile Acid Synthesis

## Interventions

- **DRUG:** Cholic acid

## Key facts

- **NCT ID:** NCT01115582
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01115582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01115582, "Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01115582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*